A new dawn for osteoporosis drug development

The Lancet Diabetes & Endocrinology 2026

View at publisher
Authors: The Lancet Diabetes Endocrinology
DOI: 10.1016/s2213-8587(26)00011-2
Cited by: 2

Fields of Study & Subjects

Bone Metabolism and Diseases Bone health and osteoporosis research Sphingolipid Metabolism and Signaling

Publication details

Journal / source
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Volume
14
Issue
3
Pages
187–187
Publication date
5 February 2026
Language
EN